Agile Therapeutics, Inc. (AGRX)
Company Description
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.
Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Country | United States |
Founded | 1997 |
IPO Date | May 23, 2014 |
Industry | Pharmaceuticals |
Sector | Health Care |
Employees | 30 |
CEO | Alfred Altomari |
Contact Details
Address: 101 Poor Farm Rd Princeton, New Jersey 08540-1941 United States | |
Phone | 609 683 1880 |
Website | agiletherapeutics.com |
Stock Details
Ticker Symbol | AGRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | US Dollars |
CIK Code | 0001261249 |
Key Executives
Name | Position |
---|---|
Alfred F. Altomari | Chairman and Chief Executive Officer |
Geoffrey P. Gilmore | Senior Vice President, General Counsel and Corporate Secretary |
Dr. Paul Korner M.B.A., M.D. | Senior Vice President and Chief Medical Officer |
Dennis P. Reilly | Senior Vice President and Chief Financial Officer |
Jason Butch | Vice President and Chief Accounting Officer |
Matthew Riley | Head of Investor Relations and Corporate Communications |
Amy Welsh | Vice President of Marketing |
Robert G. Conway M.E. | Senior Vice President and Chief Supply Chain Officer |
Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H. | Consultant |
Joseph D'Urso | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 24, 2022 | 8-K | Current report |
May 23, 2022 | 8-K | Current report |
May 13, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
May 12, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
May 12, 2022 | 8-K | Current report |
Apr 29, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 29, 2022 | DEF 14A | Other definitive proxy statements |
Apr 27, 2022 | 8-K | Current report |
Apr 27, 2022 | 424B5 | Prospectus [Rule 424(b)(5)] |
Apr 26, 2022 | 8-K | Current report |
View All SEC Filings |